Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Innovent Biologics (IVBIY) secures second Chinese approval for lung cancer therapy Dovbleron developed with U.S. biotech ...

Innovent Biologics (IVBIY) collaborates with Roche (RHHBY) to develop the antibody-drug conjugate IBI3009 for small cell lung ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.

ET Net News Agency, 8 January 2025] A direct manual trade of 1.67 million shares of INNOVENT BIO (01801) was registered at 1:00p.m. The deal amounted to HK$56.6m, or at HK$33.8 p ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...

SAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...